Company Overview
Advancing imaging technologies to support more informed cancer detection, characterisation and monitoring.
Advancing Precision Cancer Imaging.
Transforming Oncology Through Innovation.
Improving Insights Into Cancer.
About TrivarX
TrivarX Limited is an ASX-listed biotechnology company developing imaging-focused technologies designed to improve the detection, characterisation and monitoring of cancer.
The Stabl-Im Program
The company’s lead program, Stabl-Im, is exploring the use of stable isotope labelling with MRI to provide additional information about tumour biology.
The approach is intended to investigate biological features associated with tumour activity, cell turnover and treatment-related changes using non-radioactive stable isotopes and existing MRI infrastructure.
Clinical Focus
TrivarX is initially focused on brain cancers and metastatic disease, where improved in-situ characterisation may support clinical decision making.
The company is progressing Stabl-Im through technical, regulatory and clinical development planning and execution, including preparation for a clinical feasibility study to commence CY26.
Advancing Precision Oncology
TrivarX is supported by scientific, regulatory, clinical and strategic advisors and is focused on advancing practical imaging solutions for precision oncology.